Acadia Pharmaceuticals Inc. Files 8-K

TL;DR

ACADIA entered a material definitive agreement and reported other events on 5/15.

AI Summary

On May 15, 2025, Acadia Pharmaceuticals Inc. entered into a material definitive agreement. The company also reported on other events on this date. The filing was made on May 20, 2025.

Why It Matters

This filing indicates Acadia Pharmaceuticals Inc. has entered into a significant agreement and is reporting other material events, which could impact its business operations and stock.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting a material definitive agreement and other events, without immediate negative financial implications disclosed.

Key Players & Entities

• ACADIA PHARMACEUTICALS INC (company) — Registrant
• May 15, 2025 (date) — Date of earliest event reported
• May 20, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of Incorporation
• 000-50768 (filing_id) — SEC File Number
• 06-1376651 (tax_id) — IRS Employer Identification No.
• 12830 El Camino Real , Suite 400 (address) — Principal Executive Offices
• San Diego (city) — Principal Executive Offices
• California (state) — Principal Executive Offices
• 92130 (zip_code) — Principal Executive Offices

FAQ

From the Filing

0001193125-25-123175.txt : 20250520 0001193125-25-123175.hdr.sgml : 20250520 20250520163151 ACCESSION NUMBER: 0001193125-25-123175 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250515 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events FILED AS OF DATE: 20250520 DATE AS OF CHANGE: 20250520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 25969346 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 8-K 1 d943674d8k.htm 8-K 8-K ACADIA PHARMACEUTICALS INC false 0001070494 0001070494 2025-05-15 2025-05-15     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025     Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   000-50768   06-1376651 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.) 12830 El Camino Real , Suite 400     San Diego , California     92130 (Address of Principal Executive Offices)     (Zip Code) Registrant’s Telephone Number, Including Area Code: (858) 558-2871 N/A (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   ACAD   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01 Entry into a Material Definitive Agreement. 210 Lease On May 15, 2025, Acadia Pharmaceuticals Inc. (the “Company”) entered into a Lease and Lease Agreement (the “210 Lease”) with 210 Associates Limited Partnership (the “Landlord”) for the lease of approximately 52,771 rentable square feet of office space (the “Premises”) located on the second floor and a portion of the third floor of 210 Carnegie Center at 210 Carnegie Center Drive, Princeton, New Jersey 08540 as the Company’s future executive office space for comm